A phase 2a, randomized, double‐blind, placebo‐controlled, three‐arm, parallel‐group study to assess the efficacy, safety, tolerability and pharmacodynamics of PF ‐06835919 in patients with non‐alcoholic fatty liver disease and type 2 diabetes
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Aim: To assess the safety, tolerability and pharmacodynamics (PD) of the ketohexokinase inhibitor PF‐06835919 in participants with non‐alcoholic fatty liver disease (NAFLD) and type 2 diabetes (T2D). Materials and methods: This double‐blind, placebo‐controlled, parallel‐group study enrolled adults with NAFLD (≥ 8% whole liver fat [WLF] using MRI proton density fat fraction [MRI‐PDFF]) and T2D on stable doses of metformin (≥ 500 mg/day). Participants received once‐daily placebo, PF‐06835919 150 or 300 mg for 16 weeks. Randomization (1:1:1) was via an interactive response technology system. Endpoints included percentage change from baseline (CFB) in WLF using MRI‐PDFF (primary endpoint) and CFB in HbA1c (co‐primary endpoint) at 16 weeks, PD, safety and tolerability. Results: Among 164 participants randomized and treated, 145 completed the treatment (placebo, n = 50; PF‐06835919 150 mg, n = 46; PF‐06835919 300 mg, n = 49). At week 16, least squares mean (90% confidence interval) percentage CFB in WLF was −5.26% (−12.86%, 2.99%), −17.05% (−24.01%, −9.46%) and −19.13% (−25.51%, −12.20%) in the placebo, PF‐06835919 150‐mg and 300‐mg groups, respectively (PF‐06835919 300‐mg group vs. placebo, P = .0288). Modest numerical reductions in HbA1c were observed in all groups that did not reach statistical significance. Treatment‐emergent adverse event incidence was similar across groups (40.7%, 45.5% and 32.7% in the placebo, PF‐06835919 150‐mg and 300‐mg groups, respectively), with no apparent dose‐related trend. Conclusions: PF‐06835919 administration over 16 weeks was generally safe and well tolerated and resulted in reductions in WLF in participants with NAFLD and T2D.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stanhope, K. L., Schwarz, J. M., Keim, N. L., Griffen, S. C., Bremer, A. A., Graham, J. L., Hatcher, B., Cox, C. L., Dyachenko, A., Zhang, W., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37385 · Cited by 1,765
Significance of HbA1c Test in Diagnosis and Prognosis of Diabetic Patients
Sherwani, S. I., Khan, H. A., Ekhzaimy, A., Masood, A., & Sakharkar, M. K. (2016) · Biomarker Insights · doi:10.4137/bmi.s38440 · Cited by 1,381
Lambert, J. E., Ramos–Roman, M. A., Browning, J. D., & Parks, E. J. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.11.049 · Cited by 1,069 · cited 4×
“However, despite modest reductions in FPG, PF06835919 did not appear to significantly lower HbA1c, as no clear difference in HbA1c, compared with placebo, was observed for either PF-06835919 150 or 300 mg. HbA1c is an indicator of long-term glycaemic control, and elevated levels correlate with an increased risk of dia…”
BackgroundInfluentialFructose metabolism and metabolic disease
Hannou, S. A., Haslam, D. E., McKeown, N. M., & Herman, M. A. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96702 · Cited by 561 · cited 1×
“In the liver, ketohexokinase (KHK), also called fructokinase, converts fructose to fructose-1-phosphate, representing the first step in fructose metabolism.(15) The resulting increase in carbohydrate metabolites activates the transcription factor carbohydrate-response element-binding protein (ChREBP),(16) to regulate…”
BackgroundHigh-fructose corn syrup: is this what's for dinner?
Duffey, K. J., & Popkin, B. M. (2008) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2008.25825c · Cited by 163
Cited by
Metabolic reprogramming in liver fibrosis
Horn, P., & Tacke, F. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.05.003 · Cited by 432
Integrative metabolism in MASLD and MASH: Pathophysiology and emerging mechanisms
Steinberg, G. R., Valvano, C. M., De Nardo, W., & Watt, M. J. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.02.033 · Cited by 240
Pharmacological treatment of MASLD: contemporary treatment and future perspectives
Drygalski, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136518 · Cited by 39
“The phase 2a trials NCT03969719 and NCT03256526 evaluated PF-06835919, an oral KHK inhibitor, in 164 adults with NAFLD and T2DM [80,81].”
Metadata
- Authors
- Saxena, A. R., Lyle, S., Khavandi, K., Qiu, R., Whitlock, M., Esler, W. P., & Kim, A. M.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2023-01-17
- Volume
- 25
- Issue
- 4
- Pages
- 992-1001
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W4311399197
- Cited by
- 41
- References
- 5
- FWCI
- 4.59
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A phase 2a, randomized, double‐blind, placebo‐controlled, three‐arm, parallel‐group study to assess the efficacy, safety, tolerability and pharmacodynamics of PF ‐06835919 in patients with non‐alcoholic fatty liver disease and type 2 diabetes. https://app.cochat.ai/papers/10.1111/dom.14946
- The paper
- Saxena, A. R., Lyle, S., Khavandi, K., Qiu, R., Whitlock, M., Esler, W. P., & Kim, A. M. (2023). A phase 2a, randomized, double‐blind, placebo‐controlled, three‐arm, parallel‐group study to assess the efficacy, safety, tolerability and pharmacodynamics of PF ‐06835919 in patients with non‐alcoholic fatty liver disease and type 2 diabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.14946
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.